Download Free Value Creation In The Pharmaceutical Industry Book in PDF and EPUB Free Download. You can read online Value Creation In The Pharmaceutical Industry and write the review.

This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
The processes of discovery, testing and distribution of new medicines have undergone radical change in recent decades, from a focus on small molecule drugs to biomedicine and related technologies. Bruce Rasmussen very effectively draws upon modern theories of the firm, data analysis, and case studies to provide important insights into the consequences of this change. He offers convincing evidence that contradicts the widely-held view that the biopharmaceutical sector has not generated considerable economic value. Frank R. Lichtenberg, Columbia University, US Bio- and pharmaceutical industry discovery is a distressed asset today. Why? Bruce Rasmussen s book is a timely and very informative work, building on rich data sources and extensive economic research, on a subject of concern to us all. Is medicine discovery in permanent decline? Are the biotechnology and traditional pharma groups on a collision course, will the traditional group absorb the new, will integration take place, will a new discovery model emerge? I commend Bruce s book to all who wish to understand what is happening. David W. Anstice, Merck & Co., Inc. This path-breaking book addresses the ongoing implications for traditional pharmaceutical companies and biopharmaceutical start-ups of the realignment of the industry knowledge-base. The theoretical approach draws on the modern theory of the firm and related ideas in order to better define the concept of the business model, which is employed to guide the case studies and empirical analysis in the book. The author shows that while traditional pharmaceutical companies have successfully adjusted their business models to meet the challenges of biotechnology, biopharmaceutical start-ups have experienced more problems. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. However, this has been captured disproportionately by a handful of large, fully-integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical companies. This highly focused book will be a captivating read for innovation and biopharmaceutical industry analysts, as well as advisers formulating policies to support the development of the biopharmaceutical sector. Academics working on innovation and biotechnology, as well as scientists engaged in research in the life sciences, will also find this book of particular interest.
Modern Pharmaceutical Industry: A Primer comprehensively explains the broad range of divisions in the complex pharmaceutical industry. Experts actively involved in each component discuss their own contribution to a pharmaceutical company's work and success. Divisions include regulatory affairs, research and development, intellectual property, pricing, marketing, generics, OTC, and more. The seventeen chapters included in this resource offer a wide range of topics, from discovery and formulation to post-approval and legal. Readers will be given a detailed look at the structure of a contemporary drug company and a thorough understanding of what goes on behind the scenes. Modern Pharmaceutical Industry: A Primer is a valuable resource for all pharmacy students, new hires at pharmaceutical companies, drug company management, and academic health center libraries. No other text provides a comprehensive look at one of the most dynamic industries related to the modern healthcare system.
Bachelor Thesis from the year 2005 in the subject Business economics - Business Management, Corporate Governance, grade: First Class (83%), University of London (School of Management), 52 entries in the bibliography, language: English, abstract: This research paper analyses the strategic and managerial rationale for M&A activity in the pharmaceutical industry in the case of Sanofi-Aventis. The first two sections provide the conceptual and theoretical framework for this research. First, the concepts of M&A and synergy will be defined; then, a selection of the major theories and literature on M&A from the strategic and managerial schools will be introduced and explained. Consequently, according to the deductive logic, the third section will hypothesize the rationale for Sanofi-Synthelabo to acquire Aventis derived from the general theories on M&A. The subsequent sections represent the main part of the research paper, which deals with testing the hypothesis in the case of the Sanofi-Aventis merger. After having stated the hypotheses, the methodology is provided which analyses and justifies the methods used to test the hypotheses. Then, the pharmaceutical industry and its characteristics, as well as both, Sanofi-Synthelabo and Aventis will be briefly analysed. Finally, the hypotheses are tested on their validity through comparison with the key findings of the research, revealing the strategic and managerial rationale for Sanofi-Synthelabo to acquire Aventis.
Written by a global team of top managers and senior McKinsey experts, this expanded and completely revised second edition provides a wide-ranging manual on the subject of value creation in the chemical industry. Drawing on extensive first-hand management experience, several hundred consulting engagements, and in-depth research projects, the authors outline the key ingredients for managing chemical companies successfully. The book addresses in detail key issues of strategy and industry structure, describes best practice in the core functions of the chemical business system, looks at the state of the art in organization and post-merger management, and covers a selection of the most important current topics such as industrial biotechnology, the role of private equity, and the chemical landscape in China. Although mainly directed at executives and managers in the chemical industry, the knowledge contained in this comprehensive overview will also benefit scientists, engineers, investors, students, and anyone else dealing with management issues in this sector.

Best Books